Division of Vascular and Endovascular Surgery, Gonda Vascular Center, Mayo Clinic, Rochester, MN 55905, USA.
Semin Vasc Surg. 2010 Mar;23(1):36-46. doi: 10.1053/j.semvascsurg.2009.12.005.
Treatment of chronic mesenteric ischemia has evolved during the last 2 decades. Endovascular treatment has first emerged as an alternative to bypass in the elderly or higher-risk patient, but has become the primary modality of treatment in most patients with suitable lesions, independent of their surgical risk. Open mesenteric revascularization with bypass or (rarely) endarterectomy still has an important role in the treatment of patients with more extensive disease, including long-segment or flush occlusions, small vessel size, multiple tandem lesions, and severe calcification. Our preference for open reconstruction in good-risk patients with multivessel disease is a supraceliac aorta to celiac and superior mesenteric artery (SMA) bypass, whereas an iliac artery to SMA bypass or, occasionally, an infrarenal aortic to SMA bypass is used in the higher-risk group. In this article, we summarize the selection criteria, techniques, and outcomes of open mesenteric reconstruction in the endovascular era.
在过去的 20 年中,慢性肠系膜缺血的治疗方法已经发展。血管内治疗最初作为老年人或高风险患者旁路手术的替代方法出现,但已成为大多数有合适病变的患者的主要治疗方式,而与手术风险无关。开放肠系膜血运重建伴旁路或(罕见)内膜切除术在治疗更广泛疾病的患者中仍具有重要作用,包括长段或弥漫性闭塞、小血管尺寸、多个串联病变和严重钙化。我们在多血管病变的低风险患者中优先选择开放重建,即腹腔干和肠系膜上动脉(SMA)的超腔主动脉旁路术,而对于高风险患者,则使用髂动脉至 SMA 旁路术或偶尔使用肾下主动脉至 SMA 旁路术。本文总结了血管内时代开放肠系膜重建的选择标准、技术和结果。